Nevertheless, the metabolic impairments we observed suggest that polyol pathway flux may yield biomarkers of clinical risk associated with FKRP-related dystroglycanopathy. The gene discussed is FKRP; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.